NUVL•prnewswire•
Nuvalent Announces Pricing of Public Offering of Common Stock
Summary
CAMBRIDGE, Mass., Nov. 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an underwritten public offering of...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2025 by prnewswire